Should We Genetically Modify Our Children?
By Jessica Cussins,
Kennedy School Review
| 12. 07. 2015
Now that we have the power to permanently alter humanity, should we?
This was the question at the heart of the International Summit on Human Gene Editing in Washington, D.C., last week, an event co-hosted by the U.S. National Academy of Sciences and of Medicine, the Chinese Academy of Sciences, and the U.K.’s Royal Society. For three days, hundreds of scientists, scholars, and public interest advocates (and thousands others online and at #GeneEditSummit) discussed the scientific, social, ethical, and legal considerations posed by the prospect of making alterations to the human genetic code.
The summit was set in motion with the advent of a new gene-editing technology known as CRISPR. The technique was discovered just three years ago, more than a decade after other gene-editing technologies. Unlike previous methods, CRISPR is cheap and easy to use, and caused an explosion in research and interest. The U.S. National Institute of Health invested more than $80 million in CRISPR in 2014, and nearly 600 papers about the new technique were published by the end of that year.
All of the potential...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...